Table 2 Outcomes of etomidate vs. control groups
From: Etomidate and mortality in cirrhotic patients with septic shock
| Â | Etomidate | Control | P-Value |
|---|---|---|---|
| Â | N = 23 | N = 39 | Â |
ICU mortality, No. (%) | 21 (91) | 25 (64) | 0.02 |
Hospital mortality, No. (%) | 23 (100) | 37 (95) | 0.23 |
28-day mortality, No. (%) | 21 (91) | 33 (84) | 0.45 |
Delta norepinephrine (D2-1) (μ/kg/min), mean ± SD | 0.03 ± 0.30 | -0.01 ± 0.26 | 0.61 |
Delta norepinephrine (D3-1) (μ/kg/min), mean ± SD | 0.07 ± 0.37 | -0.06 ± 0.33 | 0.15 |
ICU length of stay (days), mean ± SD | 12.6 ± 7.8 | 9.4 ± 5.8 | 0.06 |
Ventilation-free days, mean ± SD | 2.3 ± 4.6 | 6.0 ± 7.5 | 0.02 |
Vasopressor-free days, mean ± SD | 3.2 ± 6 | 5.5 ± 7.8 | 0.23 |